International Society for the Study of Women's Sexual Health

NEWS

General Statement of the International Society for the Study of Women's Sexual Health

The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.

The meeting culminates the prolonged development of flibanserin, a drug that could be the first approved medical treatment for distressing low sexual desire. Flibanserin offers a favorable safety and efficacy profile for the treatment of Hypoactive Sexual Desire Disorder in women. While we fully endorse the FDA's evidence-based review of the risks and benefits of this treatment, ISSWSH wishes to emphasize the significant unmet need for safe and effective medical therapies to address all women's sexual problems.

Save the Date


ISSWSH Fall Course 2017

  November 2-4, 2017  13 days left
  DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...


ISSWSH Annual Meeting 2018

  February 8-11, 2018  111 days left
  Hilton San Diego on Mission Bay
San Diego, CA, USA

Read more...

Latest Tweets

Learn state of the art info on sexual health in pregnancy and the post-partum ISSWSH Fall Course, Nov 2-4, Scottsdale #ISSWSH2017 ISSWSH
Opinion: On the relevance of maintaining subjective #arousal disorder in the diagnostic nomenclature https://t.co/vJ6EERT31P ISSWSH
Learn about the relationship between #sexual and #cardiovascular #health in women: DOI: https://t.co/eRjbjrr0Ym ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville MN, 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (612) 808 0491
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.